Literature DB >> 9139936

Cardiac function in genetically engineered mice with altered adrenergic receptor signaling.

H A Rockman1, W J Koch, R J Lefkowitz.   

Abstract

In disease states such as heart failure, catecholamines released from sympathetic nerve endings and the adrenal medulla play a central role in the adaptive and maladaptive physiological response to altered tissue perfusion. G protein-coupled receptors are importantly involved in myocardial growth and the regulation of contractility. The adrenergic receptors themselves are regulated by a set of specific kinases, termed the G protein-coupled receptor kinases. The study of complex systems in vivo has recently been advanced by the development of transgenic and gene-targeted "knockout" mouse models. Combining transgenic technology with sophisticated physiological measurements of cardiac function is an extremely powerful strategy for studying the regulation of myocardial contractility in normal animals and in models of disease states. The purpose of this review is to summarize current knowledge about the regulation of cardiovascular homeostasis involving signaling pathways through stimulation of adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139936     DOI: 10.1152/ajpheart.1997.272.4.H1553

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 2.  Thyroid hormone and blood pressure regulation.

Authors:  Sara Danzi; Irwin Klein
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

3.  Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice.

Authors:  N Saadane; L Alpert; L E Chalifour
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 4.  The ins and outs of adrenergic signaling.

Authors:  Martin J Lohse
Journal:  J Mol Med (Berl)       Date:  2015-07-23       Impact factor: 4.599

5.  Does selective beta-1 blockade provide bone marrow protection after trauma/hemorrhagic shock?

Authors:  Latha V Pasupuleti; Kristin M Cook; Ziad C Sifri; Srinath Kotamarti; Gabriel M Calderon; Walter D Alzate; David H Livingston; Alicia M Mohr
Journal:  Surgery       Date:  2012-09       Impact factor: 3.982

6.  Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.

Authors:  C Pellieux; T Sauthier; A Domenighetti; D J Marsh; R D Palmiter; H R Brunner; T Pedrazzini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy.

Authors:  C H Redfern; M Y Degtyarev; A T Kwa; N Salomonis; N Cotte; T Nanevicz; N Fidelman; K Desai; K Vranizan; E K Lee; P Coward; N Shah; J A Warrington; G I Fishman; D Bernstein; A J Baker; B R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Authors:  Hyun Kook; John J Lepore; Aaron D Gitler; Min Min Lu; Wendy Wing-Man Yung; Joel Mackay; Rong Zhou; Victor Ferrari; Peter Gruber; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 9.  Application of mesenchymal stem cells for the regeneration of cardiomyocyte and its use for cell transplantation therapy.

Authors:  Keiichi Fukuda
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

10.  Regeneration of cardiomyocytes from bone marrow: Use of mesenchymal stem cell for cardiovascular tissue engineering.

Authors:  Keiichi Fukuda
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.